Autologous Bcma/Cd19 Dual-Target Car-T Module
T-Lymphoblastic Lymphoma
Explore 45 assets in T-Lymphoblastic Lymphoma →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Beijing Biotech
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07523555CT.gov Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Lymphoblastic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Bcma/Cd19 Dual-Target Car-T Module (this asset) | Beijing Biotech | P1/2 | CC · 45 |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Asparaginase | University of Washington | P3 | BB |
| Pegaspargase | Children's Oncology Group | P3 | BB |
| Cyclophosphamide | Children's Oncology Group | P3 | BB |
| Dexasone | Children's Oncology Group | P3 | BB |
| Mercaptopurine Anhydrous | Children's Oncology Group | P3 | BB |
| Thioguanine Anhydrous | Children's Oncology Group | P3 | BB |
| Daunomycin | Children's Oncology Group | P3 | BB |
+42 more in the T-Lymphoblastic Lymphoma cohort
Other indications for Autologous Bcma/Cd19 Dual-Target Car-T Module
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukemia | — | P1/2 | CC · 47 |
| B-Cell Non-Hodgkin Lymphoma | — | P1/2 | CC · 47 |
| Plasma Cell Myeloma | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Bcma/Cd19 Dual-Target Car-T Module in T-Lymphoblastic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-bcmacd19-dual-target-car-t-module-t-lymphoblastic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →